Literature DB >> 1771222

Distribution of diazepam, nordiazepam, and oxazepam between brain extraneuronal space, brain tissue, plasma, and cerebrospinal fluid in diazepam and nordiazepam dependent dogs.

E P Wala1, W R Martin, J W Sloan.   

Abstract

The compartmental distribution of diazepam (DZ) and nordiazepam (ND) and their metabolites was studied in DZ and ND dependent dogs. The levels of DZ, and ND and their metabolites were determined during the last week of stabilization in the extraneuronal brain space, in brain tissue, in plasma and in CSF. In these studies dependent dogs were anesthetized with pentobarbital and microdialysis probes were inserted bilaterally into the parietal cortex and perfused with artificial cerebrospinal fluid. Microdialysis probes were also used to determine the unbound parent drugs and their metabolites in plasma. The brain-plasma distribution of total ND and oxazepam (OX) is about equal in ND dependent dogs but in DZ dependent dogs total ND and OX are about 2-fold higher in brain than in plasma. The levels of DZ, ND, and OX in the extraneuronal brain space are similar to their unbound levels in plasma. These data suggest that the concentration of free benzodiazepines in plasma is a good approximation of the concentration in the vicinity of the membrane receptors in the dependent dogs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1771222     DOI: 10.1007/bf02244376

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Cumulation in cerebrospinal fluid of the N-desmethyl metabolite after long-term treatment with diazepam in man.

Authors:  J Hendel
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975-07

2.  The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma.

Authors:  H Friedman; D R Abernethy; D J Greenblatt; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation.

Authors:  R K Dubey; C B McAllister; M Inoue; G R Wilkinson
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

4.  Diazepam: kinetic profiles in various brain areas, plasma and erythrocytes after chronic administration in the rat.

Authors:  C Hariton; G Jadot; E Mesdjian; P Mandel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

5.  Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats.

Authors:  J M Scavone; H Friedman; D J Greenblatt; R I Shader
Journal:  Arzneimittelforschung       Date:  1987-01

6.  Flumazenil oral absorption in dogs.

Authors:  E Wala; L F McNicholas; J W Sloan; W R Martin
Journal:  Pharmacol Biochem Behav       Date:  1988-08       Impact factor: 3.533

7.  Chronic benzodiazepine administration. I. Tolerance is associated with benzodiazepine receptor downregulation and decreased gamma-aminobutyric acidA receptor function.

Authors:  L G Miller; D J Greenblatt; J G Barnhill; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1988-07       Impact factor: 4.030

8.  Precipitated abstinence in orally dosed benzodiazepine-dependent dogs.

Authors:  W R Martin; J W Sloan; E Wala
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

9.  Precipitation of abstinence in nordiazepam- and diazepam-dependent dogs.

Authors:  L F McNicholas; W R Martin; J W Sloan; E Wala
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

10.  Entry of diazepam and its major matabolite into cerebrospinal fluid.

Authors:  D J Greenblatt; H R Ochs; B L Lloyd
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  1 in total

1.  Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method.

Authors:  M Hammarlund-Udenaes; L K Paalzow; E C de Lange
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.